FASLG and neoplasm: Additionally, exosomes from Vδ2 T cells (Vδ2-T-Exos) activate FasL and TRAIL pathways, effectively killing EBV-associated tumor cells while expanding EBV-specific CD4+ and CD8+ T cells.